HRP20192205T1 - Test inhibicije na bazi razrjeđivanja - Google Patents
Test inhibicije na bazi razrjeđivanja Download PDFInfo
- Publication number
- HRP20192205T1 HRP20192205T1 HRP20192205TT HRP20192205T HRP20192205T1 HR P20192205 T1 HRP20192205 T1 HR P20192205T1 HR P20192205T T HRP20192205T T HR P20192205TT HR P20192205 T HRP20192205 T HR P20192205T HR P20192205 T1 HRP20192205 T1 HR P20192205T1
- Authority
- HR
- Croatia
- Prior art keywords
- ace
- dilution
- inhibition
- dilution factor
- subject
- Prior art date
Links
- 238000010790 dilution Methods 0.000 title claims 14
- 239000012895 dilution Substances 0.000 title claims 14
- 230000005764 inhibitory process Effects 0.000 title claims 9
- 238000003556 assay Methods 0.000 title 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 6
- 239000005541 ACE inhibitor Substances 0.000 claims 5
- 102000004190 Enzymes Human genes 0.000 claims 5
- 108090000790 Enzymes Proteins 0.000 claims 5
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 4
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 4
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000012470 diluted sample Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (3)
1. In vitro postupak za procjenu efikasnosti enzimske inhibicije u terapiji inhibitorom angiotenzin konvertirajućeg enzima (ACE) kod subjekta koji obuhvaća:
(a) u uzorku krvi ili uzorku krvi dobivenom od subjekta koji je liječen ACE inhibitorom;
(b) uzimanje najmanje dva alikvota iz uzorka;
(c) razrjeđivanje navedenih alikvota različitim faktorima razrjeđivanja,
(d) mjerenje ACE aktivnosti u uzorcima razrjeđivanja;
(e) definiranje visokog faktora razrjeđivanja gdje efekt ACE inhibitora postaje zanemariv, pri čemu je navedeni faktor razrjeđivanja najmanje 50, poželjno najmanje 100;
(f) definiranje niskog referentnog faktora razrjeđivanja, pri čemu je navedeni faktor razrjeđivanja najviše 10;
(g) množenje izmjerenih vrijednosti aktivnosti u svakom od razblaženih uzoraka sa odgovarajućim faktorom razrjeđivanja kako bi se dobile izračunate vrijednosti ACE aktivnosti za sve uzorke razrjeđivanja;
(h) dobivanje nivoa ACE inhibicije u originalnom uzorku usporedbom vrijednosti enzimske aktivnosti utvrđenih na spomenutim faktorima niskog i visokog razrjeđivanja u navedenim uzorcima razrjeđivanja;
(i) procjenu efikasnosti medicinskog liječenja ACE inhibitorom kod spomenutog subjekta procjenjivanjem izračunatog nivoa ACE inhibicije, gdje je niska enzimska inhibicija pokazatelj neefikasne terapije, i gdje je visoka enzimska inhibicija pokazatelj efikasne terapije.
2. Postupak prema patentnom zahtjevu 1 gdje visok faktor razrjeđivanja, gdje je zanemariv efekt ACE inhibitora, je najmanje 100 ili najmanje 200, poželjno najmanje 300 ili najmanje 350 ili veoma poželjno najmanje 400,
i gdje referentni faktor niskog razrjeđivanja je najviše 20 ili najviše 10 ili veoma poželjno najviše 5 ili najviše 4, i/ili
odnos faktora razrjeđivanja je tako najmanje 10 ili poželjno najmanje 30 ili najmanje 70 ili najmanje 100.
3. Postupak patentnog zahtjeva 1, gdje se u koraku (i) inhibicija enzima smatra nedovoljnom kod subjekta koji ima nivo inhibicije, danom u postotku, niži od 90% i efikasnom kod subjekta koji ima nivo inhibicije od najmanje 90%,
čime se procjenjuje efikasnost terapije navedenim ACE inhibitorom kod spomenutog subjekta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1200299A HU230404B1 (hu) | 2012-05-18 | 2012-05-18 | Hígításon alapuló gátlóhatást mérő módszer |
| EP13168263.5A EP2664920B1 (en) | 2012-05-18 | 2013-05-17 | Dilution based inhibition assay |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192205T1 true HRP20192205T1 (hr) | 2020-02-21 |
Family
ID=89990739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192205TT HRP20192205T1 (hr) | 2012-05-18 | 2019-12-09 | Test inhibicije na bazi razrjeđivanja |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2664920B1 (hr) |
| DK (1) | DK2664920T3 (hr) |
| ES (1) | ES2761897T3 (hr) |
| HR (1) | HRP20192205T1 (hr) |
| HU (2) | HU230404B1 (hr) |
| PL (1) | PL2664920T3 (hr) |
| RS (1) | RS59757B1 (hr) |
| SI (1) | SI2664920T1 (hr) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8629312D0 (en) | 1986-12-08 | 1987-01-14 | Deacon B | Fastening devices |
| US5260872A (en) * | 1991-10-04 | 1993-11-09 | Abbott Laboratories | Automated testing system |
| ATE198772T1 (de) | 1994-11-10 | 2001-02-15 | Dade Behring Marburg Gmbh | Verfahren zum spezifischen nachweis eines aktivierten gerinnungsfaktors v mit einer erhöhten stabilität gegenüber aktiviertem protein c |
| WO2001085985A1 (en) | 2000-05-05 | 2001-11-15 | United States Army Medical Research And Material Command | Assay for detecting, measuring and monitoring the activities and concentrations of proteins and methods of use thereof |
| US6586198B2 (en) * | 2000-10-31 | 2003-07-01 | Vanderbilt University | Method of identifying susceptibility to angiotensin converting enzyme inhibto- and vasopeptidase-inhibitor-associated angioedema |
| WO2003025561A1 (fr) | 2001-09-14 | 2003-03-27 | Chugai Seiyaku Kabushiki Kaisha | Procede de mesure simultanee de la valeur rb et du taux de liaison aux proteines plasmatiques |
| US6821744B2 (en) | 2002-10-29 | 2004-11-23 | Roche Diagnostics Operations, Inc. | Method, assay, and kit for quantifying HIV protease inhibitors |
| EP1954822A1 (en) * | 2005-11-23 | 2008-08-13 | Georg Dewald | Detection and treatment of drug associated angioedema |
-
2012
- 2012-05-18 HU HU1200299A patent/HU230404B1/hu not_active IP Right Cessation
-
2013
- 2013-05-17 SI SI201331634T patent/SI2664920T1/sl unknown
- 2013-05-17 EP EP13168263.5A patent/EP2664920B1/en active Active
- 2013-05-17 ES ES13168263T patent/ES2761897T3/es active Active
- 2013-05-17 DK DK13168263.5T patent/DK2664920T3/da active
- 2013-05-17 PL PL13168263T patent/PL2664920T3/pl unknown
- 2013-05-17 RS RS20191586A patent/RS59757B1/sr unknown
- 2013-05-17 HU HUE13168263A patent/HUE047866T2/hu unknown
-
2019
- 2019-12-09 HR HRP20192205TT patent/HRP20192205T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2664920A1 (en) | 2013-11-20 |
| RS59757B1 (sr) | 2020-02-28 |
| ES2761897T3 (es) | 2020-05-21 |
| SI2664920T1 (sl) | 2020-02-28 |
| HUE047866T2 (hu) | 2020-05-28 |
| HUP1200299A2 (en) | 2013-11-28 |
| PL2664920T3 (pl) | 2020-04-30 |
| HU230404B1 (hu) | 2016-04-28 |
| DK2664920T3 (da) | 2019-12-16 |
| EP2664920B1 (en) | 2019-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120434T1 (el) | Πρωτεϊνες προσδεσης il-1 | |
| AR098155A1 (es) | Métodos para diagnosticar y tratar trastornos eosinofílicos | |
| MY183402A (en) | Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof | |
| WO2013096407A3 (en) | Monitoring activation times for use in determining pacing effectiveness | |
| WO2015153864A3 (en) | Methods for treating inflammatory conditions | |
| EA201790769A1 (ru) | Определение уровней гликозаминогликанов методом масс-спектрометрии | |
| AR080361A1 (es) | Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores de quinasa del linfoma anaplasico (alk) | |
| RU2016107954A (ru) | Способы идентификации и прогнозирования риска сердечно-сосудистого события или заболевания, или смертельного исхода, способы оценки тяжести и мониторинга сердечно-сосудистого события или заболевания, способ мониторинга эффективности терапии | |
| MX2012006394A (es) | Metodos para identificar plantas de frijol tolerantes a sequia. | |
| BR112015000685A2 (pt) | método para a identificação de risco clínico em um paciente possuindo ou suspeito de possuir uma infecção por influenza, método para a identificação de influenza ou pneumonia viral em um paciente, kit, método para avaliar a eficácia de um agente para o tratamento de influenza e para reduzir a severidade da doença em um indivíduo exposto a um vírus influenza. | |
| BR112016010159A2 (pt) | usos de um conjunto de ácidos nucleicos e de um chip de microarranjo, chip de microarranjo, métodos para detecção de patógenos e/ou microrganismos benéficos em uma amostra orgânica e de tratamento de uma relva doente, e, kit | |
| Aggarwal | Lactate dehydrogenase as a biomarker for silica exposure-induced toxicity in agate workers | |
| HRP20192205T1 (hr) | Test inhibicije na bazi razrjeđivanja | |
| WO2016029001A3 (en) | Antibodies to polyphosphate decrease clot formation, decrease inflammation, and improve survival | |
| EP2647989A3 (de) | Verfahren zur zerstörungsfreien quantitativen Bestimmung der Mikroeigenspannung II. und/oder III. Art | |
| JP2015180198A5 (hr) | ||
| RU2008128156A (ru) | Способ прогнозирования эффективности лечения бронхиальной астмы | |
| BR112014018709A8 (pt) | Composições e efetores de beta-arrestina e métodos de uso dos mesmos | |
| RU2012141281A (ru) | Способ лабораторной оценки эффективности антибактериальной терапии | |
| BR112014027413A2 (pt) | biomarcadores para terapia com inibidor de iap | |
| JP2014208601A5 (hr) | ||
| AR097591A1 (es) | Métodos para determinar la respuesta a la terapia | |
| BR112014007947A2 (pt) | método para monitoramento, diagnóstico e/ou prognóstico de distúrbios relacionados à hipoxia usando nfat5 | |
| RU2013144627A (ru) | Способ оценки эффективности диализно-фильтрационной очистки крови | |
| RU2014126297A (ru) | Способ оценки активности туберкулемы |